[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Combined Military Hospital Abbottabad\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100649074","phase-4-oral-tranexamic-acid-plus-triple-combination-vs-triple-combination-alone-in-melasma-100649074",false,"NCT07732192","Oral Tranexamic Acid Plus Triple Combination vs Triple Combination Alone in Melasma","Comparative Efficacy of Oral Tranexamic Acid With Triple Combination (Fluocinolone+ Hydroquinone +Tretinoin) Versus Triple Combination Alone in Melasma in a Tertiary Care Hospital","Inclusion Criteria: Patients aged 18 to 50 years of either gender with clinically diagnosed epidermal or mixed melasma of at least six months duration and baseline MASI score above the predefined threshold will be included. Patients willing to comply with treatment and follow-up schedule will be enrolled.\n\n\\-\n\nExclusion Criteria: Patients with dermal melasma, pregnancy, lactation, history of thromboembolic disease, coagulation disorders, current hormonal therapy use, recent treatment for melasma, hypersensitivity to study medications, or significant hepatic or renal disease will be excluded.\n\n\\-","ALL","18 Years","50 Years",{"count":20,"type":21},128,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The data will be collected after the permission of the ethical committee of hospital. Following the enrollment, patients will be selected by lottery in the two equal groups. Group A will be administered with oral tranexamic acid and triple combination therapy whereas Group B will be treated with triple combination therapy. Strict use of sunscreens and sun protection will be promoted to all patients. Group A will administer oral tranexamic acid with the prescribed dose of the study drug along with topical application of fluocinolone acetonide, hydroquinone and tretinoin at bedtime. Group B will be treated by triple combination therapy only once a day at night. The study will continue to treatment. There will be a baseline MASI score which will be taken prior to the onset of treatment and re-evaluated at the planned follow-ups. The main outcome will be the decrease in the MASI score and the percentage of the patients who will be responding to treatment. The negative effects and recurrence in the follow-up will be considered as secondary outcomes. The structured proforma will gather data on age, gender, melasma duration, skin phototype, baseline MASI score, treatment group, follow-up MASI score, percentage improvement, adverse effects and treatment response. The principal investigator will document all the findings.",[27,28],"Melasma","Melasma (Facial Melasma)",[30,31,27,32],"Tranexamic Acid","MASI Score","Triple Combination Therapy","NOT_YET_RECRUITING","2026-07-23",{"date":36,"type":37},"2026-07-28","ACTUAL",{"date":39,"type":21},"2026-07-15",{"date":41,"type":21},"2027-02-01",{"name":43,"class":44},"Combined Military Hospital Abbottabad","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100638862","comparative-efficacy-of-intralesional-tranexamic-acid-versus-mandelic-acid-peel-in-the-treatment-of-melasma-100638862","NCT07604844","Comparative Efficacy of Intralesional Tranexamic Acid Versus Mandelic Acid Peel in the Treatment of Melasma","Inclusion Criteria:\n\nAge 18-45 years. Clinical diagnosis of facial melasma. Fitzpatrick skin phototypes III-V. Disease duration of at least 3 months.\n\nExclusion Criteria:\n\nPregnancy or lactation. Known hypersensitivity to tranexamic acid or mandelic acid. Active facial dermatoses or infection. Personal or family history of thromboembolic disease. Coagulation disorders. Systemic retinoid use within 6 months. Oral contraceptive or hormone replacement therapy within 6 months. Use of topical or systemic depigmenting agents within 4 weeks. History of keloid tendency.","45 Years",{"count":53,"type":21},120,[55],"NA","Melasma is a chronic acquired disorder of facial hyperpigmentation that significantly affects quality of life. Both intralesional tranexamic acid and mandelic acid chemical peels are effective treatment options with favorable safety profiles in darker skin types. However, comparative evidence in South Asian populations is limited. This study aims to compare the efficacy, safety, quality of life outcomes, and patient satisfaction of intralesional tranexamic acid versus mandelic acid peel in patients with facial melasma treated at Combined Military Hospital Abbottabad.",[27],[27,30,59,60,61,62,63],"Mandelic Acid","Chemical Peel","Hyperpigmentation","MELASQoL","Pakistan","2026-05-24",{"date":66,"type":37},"2026-05-28",{"date":68,"type":21},"2026-05",{"date":70,"type":21},"2026-10",{"name":43,"class":44},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100618451","phase-1-comparative-efficacy-of-topical-1-clotrimazole-vs-oral-itraconazole-in-the-treatment-of-pityriasis-versicolor-100618451","NCT07331792","Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor","Inclusion Criteria:\n\n* Age (15-50 years)\n* Both genders\n* Sufferers of Pityriasis versicolor ( Determined by scale , erythema and pruritus)\n\nExclusion Criteria:\n\n* Pt with history of antifungals in last one month\n* Pt on immunosuppressants or steroid therapy\n* Pregnant and lactating women\n* Pt with chronic medical conditions ( Diabetes and hypertension)","15 Years",{"count":81,"type":21},86,[83,84],"PHASE1","PHASE2","Comparative efficacy of topical 1% clotrimazole vs oral itraconazole in the treatment of pityriasis versicolor -Randomized control trial",[87],"Pityriasis Versicolor","2026-01-05",{"date":90,"type":37},"2026-01-12",{"date":92,"type":21},"2026-02-02",{"date":94,"type":21},"2026-05-31",{"name":43,"class":44},""]